
Opinion|Videos|January 23, 2025
Adding Chemotherapy for a Patient Receiving ADT + an ARPI
Author(s)Evan Y. Yu, MD
Evan Y. Yu, MD, discusses how adding chemotherapy to a doublet regimen for metastatic hormone-sensitive prostate cancer may be considered on an as-needed basis, particularly for patients with high disease burden or rapid progression, while carefully weighing the potential benefits and risks of intensifying therapy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Would you consider adding chemotherapy to a doublet regimen on an as-needed basis?
Advertisement
Related to this article

During a live event, Robert Orlowski, MD, PhD, and participants discussed selinexor combinations, dosing, and nausea prevention for an older patient with late relapsed multiple myeloma who declines CAR T.

Sac-TMT improved OS vs physician’s choice in pretreated gastroesophageal adenocarcinoma in the phase 3 TroFuse-015 trial; PFS was not improved.

Updated RMC-GI-102 data show 60.7% ORR and 12.8-month median PFS with daraxonrasib plus GnP in first-line metastatic PDAC.

Modern Hodgkin lymphoma treatment is tied to a 25% drop in solid second cancers, but breast and lung cancer risks persist for decades.

ESMO data show the phase 3 INTerpath-001 trial of intismeran autogene plus pembrolizumab improved recurrence-free survival in resected stage IIB to IV melanoma.

In HypoMast-IMNI, 16-fraction radiotherapy was noninferior to 25 fractions for locoregional recurrence after mastectomy in high-risk breast cancer.

Five-year PHERGain results support PET-guided treatment de-escalation in HER2-positive breast cancer, with ctDNA offering insight into recurrence risk
Advertisement
Advertisement
Trending on Targeted Onc
1
Daraxonrasib Plus Chemo Yields Durable Response in First-Line PDAC
2
Sacituzumab Tirumotecan Improves OS in 3L+ Gastroesophageal Cancer
3
Contrasting Myeloma Therapies for Late Relapse in Patient Declining CAR T
4
Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML
5

